BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 19808697)

  • 21. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
    Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
    Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.
    Hou HA; Huang TC; Lin LI; Liu CY; Chen CY; Chou WC; Tang JL; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Blood; 2010 Jun; 115(25):5222-31. PubMed ID: 20368469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent coexistence of RAS mutations in RUNX1-mutated acute myeloid leukemia in Arab Asian children.
    Al-Kzayer LF; Sakashita K; Al-Jadiry MF; Al-Hadad SA; Uyen le TN; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Hasan JG; Al-Abdullah HM; Inoshita T; Kamata M; Sughayer MA; Madanat FF; Koike K
    Pediatr Blood Cancer; 2014 Nov; 61(11):1980-5. PubMed ID: 25066867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency and Clinicopathologic Features of RUNX1 Mutations in Patients With Acute Myeloid Leukemia Not Otherwise Specified.
    You E; Cho YU; Jang S; Seo EJ; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park YM; Lee JK; Park CJ
    Am J Clin Pathol; 2017 Jul; 148(1):64-72. PubMed ID: 28927163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
    Schnittger S; Kohl TM; Haferlach T; Kern W; Hiddemann W; Spiekermann K; Schoch C
    Blood; 2006 Mar; 107(5):1791-9. PubMed ID: 16254134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
    Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
    Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel 85-Gene Expression Signature Predicts Unfavorable Prognosis in Acute Myeloid Leukemia.
    Lai Y; Sheng L; Wang J; Zhou M; OuYang G
    Technol Cancer Res Treat; 2021; 20():15330338211004933. PubMed ID: 33784904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subtype-specific patterns of molecular mutations in acute myeloid leukemia.
    Rose D; Haferlach T; Schnittger S; Perglerová K; Kern W; Haferlach C
    Leukemia; 2017 Jan; 31(1):11-17. PubMed ID: 27285584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
    Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.
    Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Farsani MA
    Ann Hum Genet; 2017 Nov; 81(6):276-283. PubMed ID: 28895127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
    Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
    Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
    Zhao Y; Zhang T; Zhao Y; Zhou J
    Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
    Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T
    Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall.
    Menter T; Lundberg P; Wenzel F; Dirks J; Fernandez P; Friess D; Dirnhofer S; Tzankov A
    Pathobiology; 2019; 86(2-3):162-166. PubMed ID: 30396184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia.
    Tien FM; Hou HA; Tsai CH; Tang JL; Chiu YC; Chen CY; Kuo YY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Lin CT; Wu SJ; Ko BS; Hsu SC; Huang SY; Yao M; Chou WC; Tien HF
    Blood Cancer J; 2018 Aug; 8(9):87. PubMed ID: 30190467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
    Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
    Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.